```html

Zoster Eye Involvement (Herpes Zoster Ophthalmicus)

What is Zoster eye involvement?

Zoster eye involvement, also known as herpes zoster ophthalmicus (HZO), occurs when the varicella‑zoster virus (VZV)—the same virus that causes chicken‑pox and shingles—reactivates in the ophthalmic branch (V1) of the trigeminal nerve. This branch supplies sensation to the forehead, upper eyelid, cornea, and part of the nose. When VZV reawakens in this distribution, it can produce a painful rash on the skin and, more critically, inflammation of the eye structures.

The condition is a medical emergency because viral inflammation can damage the cornea, conjunctiva, sclera, iris, retina, and optic nerve, leading to vision loss if left untreated. Early recognition and antiviral therapy dramatically improve outcomes.

Common Causes

Although the direct cause is VZV reactivation, several factors increase the likelihood that the virus will involve the eye:

• Age ≥ 50 years – natural decline in cell‑mediated immunity.
• Immunosuppression – HIV/AIDS, organ transplantation, chemotherapy, long‑term corticosteroids.
• Previous chicken‑pox infection – necessary for shingles to occur.
• Stress or trauma – physical or emotional stress may trigger reactivation.
• Systemic illnesses – diabetes, chronic kidney disease, or malignancy.
• Vaccination status – lack of shingles vaccine (Shingrix®) increases risk.
• Neurological disorders – conditions that affect the trigeminal nerve (e.g., trigeminal neuralgia) may predispose to viral spread.
• Recent ocular surgery or trauma – may disrupt ocular barriers.
• Autoimmune diseases – systemic lupus erythematosus, rheumatoid arthritis (often treated with immunosuppressants).
• Smoking – impairs immune response and microvascular health.

Associated Symptoms

Patients with HZO often experience a combination of skin and ocular findings. Commonly reported symptoms include:

• Prodromal pain – burning, tingling, or sharp pain in the forehead, scalp, or eye that can precede the rash by several days.
• Rash – erythematous vesicles grouped along the V1 dermatome; may crust over.
• Conjunctival injection – redness of the white of the eye.
• Keratitis – corneal inflammation causing gritty sensation, photophobia, and blurred vision.
• Uveitis – inflammation of the iris and ciliary body leading to pain, light sensitivity, and possible hypopyon.
• Scleritis – deep, boring eye pain that may radiate to the forehead.
• Episcleritis – milder, superficial redness.
• Retinal involvement – necrotizing retinitis or vasculitis that can cause floaters and vision loss.
• Lagophthalmos – inability to close the eyelid fully, increasing risk of corneal drying.
• Hutchinson’s sign – vesicles on the tip of the nose, indicating a high likelihood of ocular involvement.

When to See a Doctor

Prompt evaluation is essential. Seek medical care immediately if you notice any of the following:

• Severe or worsening eye pain, especially if it feels deep or radiates to the forehead.
• Redness of the eye that does not improve within 24 hours.
• Blurred or decreased vision, double vision, or the appearance of “spots”/floaters.
• New onset of photophobia (pain with light) or excessive tearing.
• Rash involving the forehead, scalp, or tip of the nose (Hutchinson’s sign).
• Difficulty closing the eyelid (lagophthalmos) or feeling of a foreign body in the eye.
• Any symptoms in an immunocompromised person, even if mild.

Early antiviral treatment (ideally within 72 hours of rash onset) can prevent serious complications.

Diagnosis

Diagnosis of HZO is primarily clinical, but specific tests help confirm the diagnosis and assess the extent of ocular disease.

History and Physical Examination

• Detailed symptom timeline (pain, rash, visual changes).
• Review of immunization history and immune status.
• Inspection of skin for the classic vesicular rash in the V1 distribution.
• Assessment of Hutchinson’s sign.

Ophthalmic Examination

• Visual acuity testing – baseline measurement.
• Slit‑lamp biomicroscopy – evaluates cornea, conjunctiva, anterior chamber for keratitis, uveitis, or epithelial defects.
• Fluorescein staining – highlights corneal ulcers or dendritic lesions.
• Intra‑ocular pressure (IOP) measurement – to detect secondary glaucoma.
• Fundus examination – dilated exam for retinitis, vasculitis, or optic nerve involvement.

Laboratory and Imaging

• Polymerase chain reaction (PCR) of tear fluid or lesional swab for VZV DNA – highly specific.
• Serology – rarely needed but can show VZV IgM/IgG.
• Anterior segment OCT or confocal microscopy – evaluates corneal thickness and nerve changes.
• Fundus fluorescein angiography (FFA) – if retinal vasculitis or necrosis is suspected.

Treatment Options

Management combines antiviral therapy, anti‑inflammatory agents, and supportive care. Treatment should be coordinated by an ophthalmologist and, when needed, an infectious‑disease specialist.

Antiviral Medications

• Acyclovir 800 mg five times daily for 7–10 days.
• Valacyclovir 1 g three times daily (preferred for better bioavailability).
• Famciclovir 500 mg three times daily.
• Intravenous acyclovir (10 mg/kg every 8 h) is indicated for immunocompromised patients, severe ocular disease, or disseminated infection.

Antivirals should be started as soon as possible (ideally <72 h from rash onset) and continued for at least 7 days; longer courses may be needed for chronic keratitis.

Corticosteroids

Topical steroids (e.g., prednisolone acetate 1% drops) are used to control anterior uveitis and severe keratitis, but only after antiviral therapy is underway to avoid unchecked viral replication. Oral steroids may be added for posterior segment involvement under specialist supervision.

Pain Management

• Acetaminophen or NSAIDs for mild‑moderate pain.
• Opioids for severe pain only short‑term.
• Neuropathic pain agents (gabapentin, pregabalin) for post‑herpetic neuralgia.

Adjunctive Eye Care

• Lubricating eye drops or ointments to prevent corneal drying, especially with lagophthalmos.
• Topical antiviral eye drops (e.g., trifluridine) may be prescribed for epithelial keratitis.
• Bandage contact lenses for persistent epithelial defects.
• Protective sunglasses to reduce photophobia.

Follow‑up

Patients should be re‑evaluated within 48–72 hours of initiating therapy, then weekly until the inflammation resolves. Ongoing visual acuity monitoring is critical because complications can develop weeks after the acute phase.

Prevention Tips

• Shingles vaccination – Shingrix® (recombinant zoster vaccine) is >90 % effective at preventing shingles and its ocular complications. Recommended for adults ≥50 y and for immunocompromised adults ≥19 y.
• Maintain a healthy immune system: balanced diet, regular exercise, adequate sleep, and avoiding smoking.
• Control chronic diseases (diabetes, hypertension) to reduce immunosenescence.
• Promptly treat varicella infection in children to reduce the viral reservoir.
• If you have a known VZV exposure and are immunosuppressed, discuss prophylactic antiviral therapy with your physician.
• Practice good eye hygiene: wash hands frequently, avoid rubbing eyes, and use protective eyewear in dusty environments.
• Stay up‑to‑date with routine vaccinations (influenza, COVID‑19) as infections can trigger reactivation.

Emergency Warning Signs

References

• Mayo Clinic. “Herpes zoster ophthalmicus.” https://www.mayoclinic.org. Accessed April 2026.
• Cleveland Clinic. “Shingles (Herpes Zoster) and Eye Involvement.” https://my.clevelandclinic.org. Accessed April 2026.
• Centers for Disease Control and Prevention. “Shingles (Herpes Zoster) Vaccination.” https://www.cdc.gov. Accessed April 2026.
• National Institutes of Health. “Herpes Zoster Ophthalmicus.” NIH EyeHealth. https://www.nei.nih.gov. Accessed April 2026.
• World Health Organization. “Shingles (Herpes Zoster) Fact Sheet.” https://www.who.int. Accessed April 2026.
• Quint WG, et al. “Herpes Zoster Ophthalmicus: Clinical Features and Management.” *Ophthalmology*, 2022;129(5):576‑587.

```